PL3700902T3 - Inhibitory trpc6 - Google Patents

Inhibitory trpc6

Info

Publication number
PL3700902T3
PL3700902T3 PL18800513.6T PL18800513T PL3700902T3 PL 3700902 T3 PL3700902 T3 PL 3700902T3 PL 18800513 T PL18800513 T PL 18800513T PL 3700902 T3 PL3700902 T3 PL 3700902T3
Authority
PL
Poland
Prior art keywords
trpc6
inhibitors
Prior art date
Application number
PL18800513.6T
Other languages
English (en)
Inventor
Thierry Bouyssou
Dirk Gottschling
Niklas Heine
Lana Louise Smith Keenan
Michael D. Lowe
Hossein Razavi
Christopher Ronald Sarko
Simon Surprenant
Hidenori Takahashi
Michael Robert Turner
Xinyuan Wu
Original Assignee
Boehringer Ingelheim International Gmbh
Hydra Biosciences, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Hydra Biosciences, Llc filed Critical Boehringer Ingelheim International Gmbh
Publication of PL3700902T3 publication Critical patent/PL3700902T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL18800513.6T 2017-10-27 2018-10-25 Inhibitory trpc6 PL3700902T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762577883P 2017-10-27 2017-10-27
US201862628313P 2018-02-09 2018-02-09
PCT/EP2018/079276 WO2019081637A1 (en) 2017-10-27 2018-10-25 CARBONYL PYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USES AS TRPC6 INHIBITORS

Publications (1)

Publication Number Publication Date
PL3700902T3 true PL3700902T3 (pl) 2023-09-04

Family

ID=64270818

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20197194.2T PL3786160T3 (pl) 2017-10-27 2018-10-25 Pochodne pirydyny i ich zastosowania terapeutyczne jako inhibitory trpc6
PL18800513.6T PL3700902T3 (pl) 2017-10-27 2018-10-25 Inhibitory trpc6

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL20197194.2T PL3786160T3 (pl) 2017-10-27 2018-10-25 Pochodne pirydyny i ich zastosowania terapeutyczne jako inhibitory trpc6

Country Status (31)

Country Link
US (4) US10889568B2 (pl)
EP (2) EP3786160B1 (pl)
JP (2) JP7217273B6 (pl)
KR (2) KR102724066B1 (pl)
CN (1) CN111527078B (pl)
AU (2) AU2018355743B2 (pl)
CA (1) CA3078769A1 (pl)
CL (2) CL2020001097A1 (pl)
CY (1) CY1126109T1 (pl)
DK (2) DK3786160T3 (pl)
ES (2) ES2946274T3 (pl)
FI (1) FI3700902T3 (pl)
HR (2) HRP20230502T1 (pl)
HU (2) HUE059450T2 (pl)
IL (2) IL274039B (pl)
LT (2) LT3700902T (pl)
MX (1) MX387232B (pl)
MY (1) MY202126A (pl)
NZ (1) NZ763816A (pl)
PE (1) PE20210154A1 (pl)
PH (1) PH12020550503A1 (pl)
PL (2) PL3786160T3 (pl)
PT (2) PT3786160T (pl)
RS (2) RS63535B1 (pl)
SA (1) SA520411843B1 (pl)
SG (2) SG10202011632RA (pl)
SI (2) SI3700902T1 (pl)
TW (2) TWI780246B (pl)
UA (1) UA128474C2 (pl)
WO (1) WO2019081637A1 (pl)
ZA (1) ZA202002372B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX387232B (es) * 2017-10-27 2025-03-18 Boehringer Ingelheim Int Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
US11485740B2 (en) * 2018-02-15 2022-11-01 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6
CN111868055B (zh) * 2018-02-16 2024-03-08 勃林格殷格翰国际有限公司 Trpc6的抑制剂
IL315313A (en) * 2018-08-24 2024-10-01 Xeniopro GmbH Aromatic molecules for use in the treatment of pathological conditions
WO2020208002A1 (en) * 2019-04-12 2020-10-15 Boehringer Ingelheim International Gmbh Inhibitors of trpc6
WO2021079962A1 (ja) * 2019-10-24 2021-04-29 国立大学法人大阪大学 難聴の予防および／または治療用医薬組成物
EP4103245A1 (en) 2020-02-11 2022-12-21 Klinikum rechts der Isar der Technischen Universität München Administration of calcium channel trpc6 inhibitors using balloons, stents or other medical devices
AR121846A1 (es) * 2020-04-16 2022-07-13 Teijin Pharma Ltd Derivado de arilo o heteroarilo
US20230149393A1 (en) 2020-04-16 2023-05-18 Boehringer Ingelheim International Gmbh Inhibitors of trpc6 for treating respiratory conditions
CN113105318B (zh) * 2021-02-23 2022-05-20 中山大学 一种2,2-二氟环丁烷-1-羧酸的制备方法及应用
MX2024004483A (es) 2021-10-15 2024-05-03 Boehringer Ingelheim Int Compuestos para el tratamiento de sepsis.
JP2025023360A (ja) * 2021-12-06 2025-02-17 国立大学法人 熊本大学 Ｔｒｐｃ６の発現を抑制する方法
TW202523305A (zh) 2023-08-18 2025-06-16 德商百靈佳殷格翰國際股份有限公司 用於治療局部節段性腎絲球硬化症之trpc6抑制劑

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU658134B2 (en) 1989-12-28 1995-04-06 Virginia Commonwealth University Sigma receptor ligands and the use thereof
CA2111957A1 (en) 1991-06-27 1993-01-07 Richard A. Glennon Sigma receptor ligands and the use thereof
AU673569B2 (en) 1992-12-02 1996-11-14 Pfizer Inc. Catechol diethers as selective PDE-IV inhibitors
BR9914018A (pt) 1998-09-22 2001-07-03 Yamanouchi Pharmaceuticals Co Derivado de cianofenila
ATE311366T1 (de) 2000-02-29 2005-12-15 Millennium Pharm Inc Benzamide und ähnliche inhibitoren vom faktor xa
KR20030024799A (ko) 2000-07-20 2003-03-26 뉴로젠 코포레이션 캡사이신 수용체 리간드
JP4186518B2 (ja) * 2001-06-15 2008-11-26 アステラス製薬株式会社 フェニルピリジン誘導体
WO2002102778A1 (en) * 2001-06-15 2002-12-27 Yamanouchi Pharmaceutical Co., Ltd. Phenylpyridine carbonyl piperazine derivative
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
DE10222291A1 (de) 2002-05-18 2003-11-27 Schlafhorst & Co W Faserbandzuführeinrichtung
CN1150176C (zh) 2002-05-22 2004-05-19 上海医药工业研究院 芳烷酮哌嗪衍生物及其应用
CA2581745A1 (en) 2004-10-13 2006-04-27 Neurogen Corporation Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor
DE102005044814A1 (de) 2005-05-19 2006-11-23 Grünenthal GmbH Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
PE20070795A1 (es) 2005-10-28 2007-08-24 Lilly Co Eli Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
CA2634250A1 (en) 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
JP5019768B2 (ja) 2006-03-23 2012-09-05 独立行政法人科学技術振興機構 新規低分子化合物およびその製造方法
AU2008225766B2 (en) 2007-03-15 2012-06-07 Novartis Ag Organic compounds and their uses
JP5082538B2 (ja) 2007-03-28 2012-11-28 Ｄｉｃ株式会社 ピペラジン化合物
CA2746943A1 (en) 2008-12-18 2010-07-15 Boehringer Ingelheim International Gmbh Serotonin 5-ht2b receptor inhibitors
US20100234603A1 (en) 2009-03-13 2010-09-16 Xin Linghu Process for Making Substituted Aryl Sulfone Intermediates
US20110039850A1 (en) 2009-08-12 2011-02-17 Mhairi Copland Leukemia Treatment
CA2774573A1 (en) 2009-10-09 2011-04-14 Irm Llc Compounds and compositions as modulators of gpr119 activity
PH12012500911A1 (en) 2009-11-18 2012-11-26 Novartis Ag Methods and compositions for treating solid tumors and other malignancies
WO2011109059A1 (en) 2010-03-01 2011-09-09 Gtx, Inc. Compounds for treatment of cancer
PH12012502112A1 (en) 2010-04-27 2021-06-23 Mitsubishi Tanabe Pharma Corp Novel amide derivative and use thereof as medicine
CN103221404B (zh) 2010-05-13 2015-12-16 安姆根有限公司 可用作pde10抑制剂的不饱和氮杂环化合物
ES2823350T3 (es) 2010-07-29 2021-05-06 Rigel Pharmaceuticals Inc Compuestos heterocíclicos que activan AMPK y métodos de uso de los mismos
US9586928B2 (en) 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
JP5800786B2 (ja) 2011-10-26 2015-10-28 田辺三菱製薬株式会社 新規アミド誘導体を有効成分として含有する医薬組成物
WO2013066714A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
CN103360343B (zh) 2012-03-30 2017-04-19 凯惠药业(上海)有限公司 一种哌嗪酰胺类化合物的制备方法
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
TWI642668B (zh) * 2013-05-27 2018-12-01 赫孚孟拉羅股份公司 新穎３，４－二氫－２ｈ－異喹啉－１－酮及２，３－二氫異吲哚－１－酮化合物
WO2015048547A2 (en) 2013-09-26 2015-04-02 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
CN111892589A (zh) 2014-01-06 2020-11-06 理森制药股份公司 谷氨酰胺酶抑制剂
WO2015199206A1 (ja) 2014-06-27 2015-12-30 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する６員環誘導体
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
MA41598A (fr) * 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2017066705A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
CN107176927B (zh) 2016-03-12 2020-02-18 福建金乐医药科技有限公司 组蛋白去甲基化酶lsd1抑制剂
RS64261B1 (sr) 2016-03-16 2023-07-31 Kura Oncology Inc Supstituisani derivati tieno[2,3-d]pirimidina kao inhibitori menin-mll i načini upotrebe
CN110337293A (zh) 2016-06-20 2019-10-15 新泽西鲁特格斯州立大学 治疗性化合物
CN107540636A (zh) 2016-06-29 2018-01-05 成都贝斯凯瑞生物科技有限公司 一种含氮杂环衍生物及其应用
CN106317050B (zh) * 2016-08-24 2018-11-23 烟台大学 一种苯基噻唑衍生物及其制备方法与应用
JPWO2018159827A1 (ja) 2017-03-03 2020-01-09 国立大学法人京都大学 植物ステロイドホルモン（ブラシノライド）様活性をもつ非ステロイド化合物の創製
TW201902875A (zh) 2017-03-15 2019-01-16 美商亞瑟尼克斯公司 聯芳基哌啶醯胺化合物及其使用方法
MX387232B (es) 2017-10-27 2025-03-18 Boehringer Ingelheim Int Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
AU2018367515B2 (en) * 2017-11-16 2023-04-27 Principia Biopharma Inc. Immunoproteasome inhibitors
US11485740B2 (en) 2018-02-15 2022-11-01 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6
CN111868055B (zh) 2018-02-16 2024-03-08 勃林格殷格翰国际有限公司 Trpc6的抑制剂

Also Published As

Publication number Publication date
DK3700902T3 (en) 2023-05-22
CL2020002562A1 (es) 2021-01-15
RS64271B1 (sr) 2023-07-31
ES2946274T3 (es) 2023-07-14
CL2020001097A1 (es) 2020-08-28
US20190169167A1 (en) 2019-06-06
MX2020004283A (es) 2021-10-21
IL274039A (en) 2020-06-30
EP3700902A1 (en) 2020-09-02
PL3786160T3 (pl) 2022-10-24
JP2021500390A (ja) 2021-01-07
UA128474C2 (uk) 2024-07-24
CA3078769A1 (en) 2019-05-02
SI3786160T1 (sl) 2022-11-30
RS63535B1 (sr) 2022-09-30
JP7217273B2 (ja) 2023-02-02
ZA202002372B (en) 2023-10-25
MX387232B (es) 2025-03-18
PH12020550503A1 (en) 2021-03-22
CN111527078B (zh) 2023-06-02
US20190169168A1 (en) 2019-06-06
FI3700902T3 (fi) 2023-05-25
NZ763816A (en) 2025-10-31
HRP20230502T1 (hr) 2023-09-15
EP3786160A1 (en) 2021-03-03
KR20200095467A (ko) 2020-08-10
SG11202003367TA (en) 2020-05-28
TWI780246B (zh) 2022-10-11
IL277493A (en) 2020-11-30
IL274039B (en) 2021-08-31
USRE49699E1 (en) 2023-10-17
PT3786160T (pt) 2022-08-19
TW201930294A (zh) 2019-08-01
SI3700902T1 (sl) 2023-10-30
LT3700902T (lt) 2023-06-26
KR20200125758A (ko) 2020-11-04
JP7217273B6 (ja) 2024-02-08
IL277493B (en) 2022-02-01
AU2020250185A1 (en) 2020-11-12
DK3786160T3 (da) 2022-08-22
EP3786160B1 (en) 2022-07-13
HUE059450T2 (hu) 2022-11-28
ES2924933T3 (es) 2022-10-11
EP3700902B8 (en) 2023-08-02
SA520411843B1 (ar) 2024-01-27
CN111527078A (zh) 2020-08-11
AU2020250185B2 (en) 2022-04-14
WO2019081637A1 (en) 2019-05-02
AU2018355743B2 (en) 2022-04-14
AU2018355743A1 (en) 2020-05-14
US10889568B2 (en) 2021-01-12
SG10202011632RA (en) 2021-01-28
CY1126109T1 (el) 2023-11-15
PE20210154A1 (es) 2021-01-26
TWI780511B (zh) 2022-10-11
US10800757B2 (en) 2020-10-13
BR112020007818A2 (pt) 2020-10-20
KR102724066B1 (ko) 2024-10-30
JP6979502B2 (ja) 2021-12-15
LT3786160T (lt) 2022-09-26
EP3700902B1 (en) 2023-03-08
TW202120494A (zh) 2021-06-01
US20210163449A1 (en) 2021-06-03
MY202126A (en) 2024-04-05
PT3700902T (pt) 2023-05-30
HRP20220991T1 (hr) 2022-11-11
HUE062460T2 (hu) 2023-11-28
JP2021008503A (ja) 2021-01-28

Similar Documents

Publication Publication Date Title
LT3700902T (lt) Trpc6 inhibitoriai
ZA201905811B (en) Novel inhibitors
IL261606A (en) Inhibitors of transfected menin-mll and methods of use
IL267291B (en) Actonucleotidase inhibitors and methods of using them
IL259794A (en) Bicyclic inhibitors for pad4
IL274504A (en) 2ACSS inhibitors and methods of their use
HUE050217T2 (hu) Brómdomén inhibitorok
SG11201802665VA (en) Ferroportin inhibitors
IL279949A (en) Heterocyclic MCT4 inhibitors
IL259796A (en) Aza-benzimidazole inhibitors of pad4
IL257061A (en) Inhibitors of ezh2
ZA201907136B (en) Ip6k inhibitors
PL3621694T3 (pl) Inhibitory lrrc33 i ich zastosowanie
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
PT3661491T (pt) 3-metilmetcatinona para uso no tratamento de um indivíduo sob uma intervenção psicoterapêutica
IL274550A (en) Dopamine-B-hydroxylase inhibitors
SG11202000621VA (en) Inhibitors of ror?
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
GB201721465D0 (en) Inhibitors
ZA201807614B (en) Bromodomain inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors
AU2017904351A0 (en) Inhibitors of necroptosis
AU2015903172A0 (en) Inhibitors of necroptosis
AU2015900416A0 (en) Inhibitors of necroptosis